Brookline Capital Management Forecasts FBRX FY2026 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Stock analysts at Brookline Capital Management issued their FY2026 earnings estimates for Forte Biosciences in a research note issued to investors on Thursday, November 14th. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings of ($2.17) per share for the year. The consensus estimate for Forte Biosciences’ current full-year earnings is ($22.50) per share. Brookline Capital Management also issued estimates for Forte Biosciences’ FY2027 earnings at ($1.66) EPS and FY2028 earnings at ($1.42) EPS.

Separately, Chardan Capital boosted their target price on shares of Forte Biosciences from $3.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

Forte Biosciences Trading Down 3.0 %

Shares of FBRX opened at $5.93 on Monday. The company has a market cap of $8.66 million, a price-to-earnings ratio of -0.36 and a beta of 0.04. Forte Biosciences has a 1-year low of $4.11 and a 1-year high of $21.25. The company’s fifty day simple moving average is $5.43 and its 200 day simple moving average is $2.41.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.